Please select your language:

Is the change in 6MWD predictive of long-term outcomes in PAH?

Utilisation of the simple and inexpensive 6-minute walk test provides valuable information about a patient's functional status and reflects activities of daily living1. As such, the change from baseline in 6-minute walk distance (6MWD) has been used as a primary endpoint in pulmonary arterial hypertension (PAH), allowing differences (e.g. improvements) in exercise capacity to be detected between the placebo and study drug arms of clinical studies. Until recently, change in 6MWD has served as the primary endpoint in all placebo-controlled pivotal trials of currently available PAH treatments, playing an important role in their regulatory approval2.

A clinical endpoint should directly measure how a patient feels, functions or survives3 and primary endpoints in PAH trials must be clinically relevant, sensitive to treatment effect, measurable and interpretable4. Although change in 6MWD has been accepted by regulatory authorities as a primary endpoint that reflects function4, it is not established as a surrogate endpoint for outcome in PAH; in fact, the validity of the improvement in 6MWD as a potential surrogate for long-term outcomes (morbidity and mortality) in PAH patients has never been thoroughly tested5. The scientific community is now asking the question ‘Is the change in 6MWD predictive of long-term outcomes in PAH?' This question is highly relevant today, given the growing recognition of the need to employ clinically meaningful primary endpoints that directly reflect disease progression3.

A number of recently published articles and editorials have examined the relationship between 6MWD and outcomes in PAH (see slide 1). Although evidence suggests that both baseline and absolute 6MWD during therapy are correlated with outcome in PAH5-9, it has become clear that a change in 6MWD with treatment is neither a reliable nor an accurate surrogate for outcome in PAH5,7,10-12 (see slide 2).

The results of a meta-analysis of 22 short-term randomised trials in PAH, involving 3112 patients, showed that there was no relationship between change in 6MWD and death, hospitalisation for PAH, initiation of PAH rescue therapy or a composite time to clinical worsening (TTCW) outcome combining these individual components11 (see slide 3). Similarly, a pooled analysis of 10 randomised controlled trials (RCTs) of PAH-specific therapies revealed that a change in 6MWD did not explain a large proportion of the treatment effect on clinical worsening10. In fact, the change in 6MWD explained only 22% of the treatment effect10 and is, therefore, not sensitive to the entire effect of treatment intervention. As such, the authors concluded that a change in 6MWD has only modest validity as a surrogate endpoint10. In support of these findings, analysis of the data from the ARIES extension study revealed that the change in 6MWD from baseline to week 12 was not predictive of 2-year survival7.

Experts at the 5th World Symposium on PH in Nice recently proposed a 4-level hierarchy for endpoints in RCTs, according to the strength in which they reflect true clinical benefit to patients13. Since 6MWD is not considered a validated surrogate in PAH, it may be included at either level 3 (non-validated surrogate) or 4 (correlate; slide 4)13. All-cause death and morbidity and mortality endpoints for PAH, however, were included in level 1, as they are considered to be true clinical efficacy measures13. As such, drugs evaluated using a morbidity and mortality primary endpoint have been highlighted in the updated treatment algorithm13. Experts at the 4th World Symposium on PH in Dana Point recommended the use of a composite clinical outcome endpoint (morbidity and mortality) as the primary endpoint for pivotal phase III PAH trials4 (see slide 5). Experts in Nice suggested that this endpoint may be enhanced with the addition of ‘worsening of PAH symptoms’14. Change in 6MWD should be used as a secondary endpoint to provide information on the effect of the tested drug on exercise capacity2,4.

The SERAPHIN study employed a composite morbidity and mortality primary endpoint15, demonstrating that it is feasible to conduct such a study and directly assess the effect of a therapy on long-term clinical outcomes.

In the phase III SERAPHIN trial, the primary endpoint was met; macitentan significantly reduced the risk of morbidity-mortality events, as measured by the composite endpoint, up to end of treatment versus placebo by 45% in the 10 mg group (97.5% CI: 24-61%; p < 0.001)15.

The effect of macitentan on 6MWD and the association between the change in 6MWD and the composite endpoint of PAH-related death or hospitalisation were explored in the SERAPHIN trial. Change in 6MWD from baseline to month 6 is not significantly associated with the risk of PAH-related death or hospitalisation (see slide 6). As such, results from the first RCT assessing long-term outcomes in PAH suggest that there is no association between changes in 6MWD and long-term clinical outcome16.

Folie1_smallbtn-zoomIn

Folie2_smallbtn-zoomIn

Folie3_smallbtn-zoomIn

Folie4_smallbtn-zoomIn

Folie5_smallbtn-zoomIn

Folie6_smallbtn-zoomIn

 
Show References

1. Rich S. The 6-minute walk test as a primary endpoint in clinical trials for pulmonary hypertension. J Am Coll Cardiol 2012; 60:1202-03.

2. Rubin LJ. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? Am J Respir Crit Care Med 2012; 186:396-7.

3. Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Curr Opin Pulm Med 2010; 16(Suppl 1):S1-9.

4. McLaughlin VV, Badesch DB, Delcroix M et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(Suppl 1):S97-107.

5. Farber HW. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Circulation 2012; 126:258-60.

6. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122:164-72.

7. Fritz JS, Blair C, Oudiz RJ et al. Baseline and follow-up six minute walk distance and BNP predict 2-year mortality in pulmonary arterial hypertension. Chest 2013; 143:315-23.

8. Humbert M, Sitbon O, Chaouat A et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122:156-63.

9. Nickel N, Golpon H, Greer M et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39:589-96.

10. Gabler NB, French B, Strom BL et al. Validation of six-minute-walk distance as a surrogate endpoint in pulmonary arterial hypertension trials. Circulation 2012; 126:349-56.

11. Savarese G, Paolillo S, Costanzo P et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension?: a meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60:1192-201.

12. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-88.

13. Galiè N, Corris PA, Frost A. et al. Updated Treatment Algorithm of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2013; 62:D60-72.

14. Gomberg-Maitland M, Bull TM, Saggar R. New trial designs and potential therapies for pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62:D82-91.

15. Pulido T, Adzerikho I, Channick R et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369:809-18.

16. Galiè N, Channick R, Delcroix M et al. Sustained effect of macitentan, a novel endothelin receptor antagonist, on exercise capacity and the association of its measure with long-term outcomes in pulmonary arterial hypertension. Eur Heart J 2013; 34(Abstract Supplement):186.

 Share this website

Click here to email this website to a colleague

 
  • Folie1_mobile
  • Folie2_mobile
  • Folie3_mobile
  • Folie4_mobile
  • Folie5_mobile
  • Folie6_mobile

Websites sponsored by Actelion

Other links

 Share this website

Click here to email this website to a colleague